[ad_1]
MALVERN, Pa., March 21, 2022 (World NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a medical-stage biopharmaceutical organization targeted on identifying, producing, and commercializing gene therapies to overcome blindness disorders and creating a vaccine to preserve lives from COVID-19, nowadays introduced the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the position successful March 18, 2022.
In this function, she will be dependable for the enhancement and execution of the Company’s fiscal system, as nicely as all company finance, accounting, and inner and exterior fiscal reporting capabilities. She will serve as a member of Ocugen’s administration crew, reporting immediately to the CEO.
Ms. Crespo has far more than 20 decades of working experience in accounting and financial management. She has been with Ocugen given that 2019, previously serving as Vice President, Corporate Controller and Treasurer. Ahead of becoming a member of the Business, she held economical leadership roles in just Aerie Prescription drugs, Aralez Prescribed drugs and Cubist Prescribed drugs in which she was responsible for economical and complex accounting and SEC reporting, which includes the implementation of new accounting criteria and the accounting and reporting of advanced transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance observe.
“Jess has been an crucial member of the Ocugen staff for virtually a few years and we are pleased to figure out her valuable contributions with this expansion of her job. The Business has seen transformational expansion over the earlier calendar year, as we function to advance the therapies in our pipeline toward regulatory approval. Jess’ information and knowledge will assistance us sustain that momentum,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Govt Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston College and is a Accredited General public Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a medical-stage biopharmaceutical organization targeted on exploring, creating, and commercializing gene therapies to overcome blindness health conditions and developing a vaccine to save life from COVID-19. Our breakthrough modifier gene remedy system has the potential to address multiple retinal ailments with just one drug — “one to a lot of,” and our novel biologic item prospect aims to provide improved treatment to clients with underserved health conditions such as wet age-linked macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-creating Bharat Biotech’s COVAXIN™ vaccine prospect for COVID-19 in the U.S. and Canadian marketplaces. For additional information and facts, make sure you pay a visit to www.ocugen.com.
Cautionary Notice on Forward-Seeking Statements
This push launch is made up of forward-hunting statements inside the meaning of The Personal Securities Litigation Reform Act of 1995, which are subject matter to pitfalls and uncertainties. We may perhaps, in some scenarios, use conditions such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other text that express uncertainty of long run events or results to determine these ahead-looking statements. Such statements are subject to several crucial things, dangers and uncertainties that may well trigger real occasions or final results to vary materially from our present-day expectations. These and other hazards and uncertainties are extra absolutely explained in our periodic filings with the Securities and Exchange Fee (“SEC”), together with the possibility things described in the section entitled “Risk Factors” in the quarterly and yearly reviews that we file with the SEC. Any ahead-wanting statements that we make in this push release communicate only as of the day of this push release. Except as essential by regulation, we presume no obligation to update ahead-seeking statements contained in this press launch irrespective of whether as a result of new data, foreseeable future situations or if not, after the date of this push launch.
Ocugen Get hold of:
Ken Inchausti
Head, Trader Relations & Communications
[email protected]
[ad_2]
Resource connection
